4D Molecular Therapeutics, Inc. Payments to Acquire Marketable Securities
4D Molecular Therapeutics, Inc. (FDMT) reported Payments to Acquire Marketable Securities of $95.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $62.04M, a 46.24% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $33.52M, a 75.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $178.10M, a 208.25% increase year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $15.24M, a 57.42% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $442.82M, a 5.31% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $467.65M, a 753.35% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $54.80M, a 64.25% decline from fiscal 2022.
- 4D Molecular Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $153.31M, a 9.05% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $95.56M 10-Q · filed 2026-08-13 | $273.65M derived: sum of 3 quarters · filed 2026-08-13 | $288.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $33.52M 10-Q · filed 2026-05-07 | $211.62M derived: sum of 2 quarters · filed 2026-05-07 | $226.86M derived: sum of 3 quarters · filed 2026-05-07 | $342.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $178.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $193.34M derived: sum of 2 quarters · filed 2026-03-18 | $308.74M derived: sum of 3 quarters · filed 2026-08-13 | $442.82M 10-K · filed 2026-03-18 |
| 2025-09-30 | $15.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $130.64M derived: sum of 2 quarters · filed 2026-08-13 | $264.72M 10-Q · filed 2025-11-10 | $322.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $115.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $249.48M 10-Q · filed 2026-08-13 | $307.26M derived: sum of 3 quarters · filed 2026-08-13 | $343.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $134.08M 10-Q · filed 2026-05-07 | $191.85M derived: sum of 2 quarters · filed 2026-05-07 | $227.65M derived: sum of 3 quarters · filed 2026-05-07 | $324.40M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $57.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $93.57M derived: sum of 2 quarters · filed 2026-03-18 | $190.33M derived: sum of 3 quarters · filed 2026-03-18 | $467.65M 10-K · filed 2026-03-18 |
| 2024-09-30 | $35.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $132.55M derived: sum of 2 quarters · filed 2025-11-10 | $409.87M 10-Q · filed 2025-11-10 | $444.52M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $96.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $374.08M 10-Q · filed 2025-08-11 | $408.73M derived: sum of 3 quarters · filed 2025-08-11 | $408.73M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $277.32M 10-Q · filed 2025-05-08 | $311.97M derived: sum of 2 quarters · filed 2025-05-08 | $311.97M derived: sum of 3 quarters · filed 2025-05-08 | $317.40M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $34.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $34.65M derived: sum of 2 quarters · filed 2025-02-28 | $40.07M derived: sum of 3 quarters · filed 2025-02-28 | $54.80M 10-K · filed 2025-02-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $5.43M derived: sum of 2 quarters · filed 2024-11-13 | $20.16M 10-Q · filed 2024-11-13 | -$80.35M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $20.16M 10-Q · filed 2024-08-08 | -$80.35M derived: sum of 3 quarters · filed 2024-08-08 | $107.59M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $14.73M 10-Q · filed 2024-05-09 | -$85.78M derived: sum of 2 quarters · filed 2024-05-09 | $102.16M derived: sum of 3 quarters · filed 2024-05-09 | $108.35M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$100.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $87.43M derived: sum of 2 quarters · filed 2024-02-29 | $93.62M derived: sum of 3 quarters · filed 2024-02-29 | $153.31M 10-K · filed 2024-02-29 |
| 2022-09-30 | $187.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $194.13M derived: sum of 2 quarters · filed 2023-11-09 | $253.82M 10-Q · filed 2023-11-09 | $286.02M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $6.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $65.88M 10-Q · filed 2023-08-09 | $98.07M derived: sum of 3 quarters · filed 2023-08-09 | $234.45M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $59.69M 10-Q · filed 2023-05-11 | $91.89M derived: sum of 2 quarters · filed 2023-05-11 | $228.26M derived: sum of 3 quarters · filed 2023-05-11 | $228.26M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $32.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $168.57M derived: sum of 2 quarters · filed 2023-03-15 | $168.57M derived: sum of 3 quarters · filed 2023-03-15 | $168.57M 10-K · filed 2023-03-15 |
| 2021-09-30 | $136.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $136.38M derived: sum of 2 quarters · filed 2022-11-08 | $136.38M 10-Q · filed 2022-11-08 | $136.38M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $0.00 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |